Treatment
As of January 2018, there are no USFDA-approved medications for the treatment of mild cognitive impairment. Moreover, as of January 2018, there is no high-quality evidence that supports the efficacy of any pharmaceutical drugs or dietary supplements for improving cognitive symptoms in individuals with mild cognitive impairment. A moderate amount of high-quality evidence supports the efficacy of regular physical exercise for improving cognitive symptoms in individuals with MCI. The clinical trials that established the efficacy of exercise therapy for MCI involved twice weekly exercise over a period of six months. A small amount of high-quality evidence supports the efficacy of cognitive training for improving some measures of cognitive function in individuals with mild cognitive impairment. Due to the heterogeneity among studies which assessed the effect of cognitive training in individuals with MCI, there are no particular cognitive training interventions that have been found to provide greater symptomatic benefits for MCI relative to other forms of cognitive training.The American Academy of Neurologys (AAN) clinical practice guideline on mild cognitive impairment from January 2018 stated that clinicians should identify modifiable risk factors in individuals with MCI, assess functional impairments, provide treatment for any behavioral or neuropsychiatric symptoms, and monitor the individuals cognitive status over time. It also stated that medications which cause cognitive impairment should be discontinued or avoided if possible.
Some of the surgeries may include duodenojejunostomy, laparoscopic duodenojejunostomy, or laparoscopic surgery.The timeline for recovery is 7 weeks. Epidemiology
No statistical information has been identified. Megaduodenum is an uncommon disease, and because of its extreme rarity of the condition only few cases has been reported in the literatures. Current Research
Since Megaduodenum is a rare disease, treatments and decisions are made based on the patients initial conditions and their responses to the provided treatments or surgeries.There are currently several ongoing clinical trials for megaduodenum. One study involves research of idiopathic megaduodenum in children which is a rare condition. The purpose of this study is to present the management of idiopathic megaduodenum in children. References
Further reading
Basilisco, G (1997). "Hereditary megaduodenum". The American Journal of Gastroenterology. 92 (1): 150–3. PMID 8995957. Law, David H.; Ten Eyck, Edward A. (1962). "Familial megaduodenum and megacystis". The American Journal of Medicine. 33 (6): 911. doi:10.1016/0002-9343(62)90222-X. Sturtevant, Mills (1939). "Megaduodenum and Duodenal Obstruction: Criteria for Diagnosis". Radiology. 33 (2): 185–8. doi:10.1148/33.2.185. Raia, Arrigo; Acquaroni, Danilo; Netto, Alipio Correa (1961). "Pathogenesis and treatment of acquired megaduodenum". The American Journal of Digestive Diseases. 6 (8): 757–71. doi:10.1007/BF02231059. PMID 13739156. S2CID 7354820. Gillespie, H. W. (1939). "Megaduodenum and Gastromegaly". British Journal of Radiology. 12 (136): 221–4. doi:10.1259/0007-1285-12-136-221. == External links ==